Back to search

University of Patras

Εξατομίκευση της θεραπείας με υδροξυουρία ασθενών με β-αιμοσφαιρινοπάθειες: μοριακή ανάλυση και αξιολόγηση φαρμακογονιδιωματικών δεικτών

Abstract

dc:description

Patients with β-hemoglobinopathies exhibit a variety of phenotypes, due to mutations located in the β-gene encoding the β-globin chain of HbA and, due to genetic variations located in modifying genes encoding important transcription factors, that act in trans to the human β-globin cluster and regulate its expression. Several studies have shown that elevated levels of fetal hemoglobin improve the clinical symptoms in adult patients with β-hemoglobinopathies.In the present study, mutations in the β-globin gene as well as genetic variants located in FLT1, ARG2, NOS2A, KLF10, MAP3K5, PDE7B, ASS1, NOS1 and TOX genes were determined. These modifying genes act in trans and seem to be involved in regulating the expression of γ-globin genes in adult patients with β-hemoglobinopathies. We recruited and genotyped 38 transfusion-dependent β-thalassemia patients (TDT), 7 non-transfusion-dependent β-thalassemia patients (NTDT), 53 healthy individuals as well as 42 compound heterozygotes with sickle cell disease/β-thalassemia of Hellenic origin. The latter group of patients was treated with hydroxyurea in order to increase their HbF levels and, as a result, improve their clinical phenotype. However, not all patients respond to this medication. The aim of the present study was to highlight genetic variants in the above-mentioned modifying genes that could be used as potential (pharmaco)genomic biomarkers. These biomarkers are associated with β-thalassemia patients’ ability to produce high or low HbF levels, thus, improving or not their clinical phenotype, as well as the patients’ response to HU treatment. Furthermore, we aimed to validate previous studies conducted in our laboratory (LPIT), as far as the above-mentioned biomarkers are concerned, including their data to ours, thus increasing our statistical sample and the validity of our results.β-globin gene mutations were determined by PCR analysis and Sanger sequencing. In order to determine the genetic variants in the above-mentioned modifying genes, PCR analysis was carried out followed either by Sanger sequencing or by RFLP or Heteroduplex Analysis. Furthermore, some cases were analyzed by allele-specific PCR.Our study revealed a statistically significant correlation between STR-5’-GCGCG-3’ of MAP3K5 gene, rs944725 of NOS2A gene and rs10483801 of ARG2 gene with hydroxyurea response in β-thalassemia/sickle cell disease compound heterozygotes. Furthermore, our study revealed a statistically significant correlation between rs2182008 of FLT1 gene, rs3191333 of KLF10 gene and rs10483801 of ARG2 gene with β-thalassemia intermedia phenotype-NTDT patients, who can produce elevated HbF levels without carrying HPFH syndromes, thus improving their clinical phenotype.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • kolliopoulou, Alexandra
  • Κολλιοπούλου, Αλεξάνδρα

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45830

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

kolliopoulou, Alexandra; Κολλιοπούλου, Αλεξάνδρα. Εξατομίκευση της θεραπείας με υδροξυουρία ασθενών με β-αιμοσφαιρινοπάθειες: μοριακή ανάλυση και αξιολόγηση φαρμακογονιδιωματικών δεικτών. University of Patras, 2019. http://hdl.handle.net/10442/hedi/45830